Navigation Links
VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
Date:4/20/2009

MMPSense(TM) 750 FAST is Presented at AACR 100th Annual Meeting

BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the introduction of its new FAST ("Fluorescent Activatible Sensor Technology") imaging agent platform for advanced imaging of key disease-associated biomarkers and drug response in vivo. Newly developed by VisEn Medical, FAST imaging agents are smaller molecule, biocompatible, activatible fluorescent agents that combine increased biomarker specificity with accelerated pharmacokinetics for advanced measurement and monitoring of key disease biomarkers in vivo. The new MMPSense 750 FAST, the first of the FAST agents to be launched by VisEn, was described today in a scientific poster presentation entitled "In vivo imaging of treatment effects using a novel near-infrared labeled agent: MMPSense 750 FAST", at the annual Scientific Sessions of the AACR (American Association of Cancer Research) 100th Annual Meeting 2009 in Denver, CO by Jeffrey D. Peterson, Ph.D., Vice President of Applied Biology at VisEn.

At the AACR 100th Annual Meeting, the Peterson et al study demonstrated the performance of MMPSense 750 FAST as a fast-acting, near-infrared imaging agent to measure tumor MMP activity in vivo and monitor treatment efficacy. In the study, administration of the agent allowed the non-invasive measurement of MMP inhibition using two different chemotherapy regimes. Using the VisEn FMT 2500(TM) quantitative tomography system, tumor fluorescence due to in vivo activation of the agent was clearly detectable as early as 4 hours after injection of the agent with the signal maximizing between 6 and 24 hours. By 96 hours, only 15% of the signal was still present in tumors. "Our study utilized MMPSense 750 FAST as a mechani
'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
2. VisEn Medical Raises $7 Million in Series B Financing
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. Cell Biosciences Launches Next-Generation Protein Characterization System
5. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
6. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
7. US Oncology Launches New Web Site
8. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
9. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
10. Selexis Launches Biosimilar Cell Line Development Program
11. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...RNewswire/ -- TechConnect World, an event bringing...d product integration in cleantech, nanotech, biot... for technology abstracts and business presentatio... in association with the Nano Science and Technolo...Sustainable Industries Organization (CTSI), will b...
(Date:12/2/2009)...irstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ;...ical company focused on endocrine therapy and onco...Administration (FDA) has granted Fast Track design... compound, perifosine (KRX-0401), for the treatmen...iopharmaceuticals, Inc. ("Keryx") ( KERX), is AEte...
(Date:12/1/2009)...ewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (N...r the fourth quarter ended December 31, 2009 of ap...ion for the fourth quarter of 2008. Included in fo...tallment payments of $12.5 million from Alexion. ... one-time $1.8 million payment from Genentech for ...
(Date:12/1/2009)...PRNewswire/ -- To address the emergence of the syn...al, a group of individuals and companies announced...ssociation (SynBIA) in Cambridge, Massachusetts la... a forum for individuals and commercial interests ...ties and its challenges, and advocate for its deve...
Breaking Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2
...3 NOVIS Pharmaceuticals, Inc. today,announced tha...been,appointed Chairman of the Board. The appointm...rd of Directors meeting and is effective immediate...20081023/CLTH043LOGO ), "I am very excited to ta...lping the company achieve its aggressive strategic...
...l., Oct. 23 Opponents of Michigan,s stem,cell res...esterday using,the tragic and universally reprehen...on to stem cell research. This ad is replete with ...ture and regulatory environment for,stem cell rese...s straight., First, examine the Proposal 2 itself...
...ia, October 23 GlaxoSmithKline Biologicals,S.A. (...n of a,collaboration agreement granting GSK exclus...e programmes, aimed at treating Alzheimer,s by,tar...K is acquiring exclusive rights to develop,and com...tes that are based,on AFFiRiS AFFiTOPE technology ...
Other Biology Technology:NOVIS Announces Appointment of John J. Arlotta as Chairman 2Anti-Stem-Cell-Research Ad Ignores Facts 2Anti-Stem-Cell-Research Ad Ignores Facts 3GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 2GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines 3
(Date:12/1/2009)...n a world first, a Monash University-led internati... to boost the output of the next generation of sol...collaboration with colleagues from the universitie...tandem dye-sensitised solar cells with a three-fol...d with previously reported tandem dye-sensitised s...
(Date:12/1/2009)... Antennas aren,t just for listening to the radio a...s to GPS devices. Research from North Carolina Sta...nna design creating shape-shifting antennas that ...ing from public safety to military deployment. , ...als, but there are limitations to how far they can...
(Date:11/30/2009)...he first comprehensive review of the state of Anta...l climate system is published this week (Tuesday 1...c Research (SCAR). The review - Antarctic Climate...esearch from the icy continent, identifies areas f...rgent questions that policy makers have about Anta...
Breaking Biology News(10 mins):Innovation puts next-generation solar cells on the horizon 2Shape shifters: Researchers create new breed of antennas 2First comprehensive review of the state of Antarctica's climate 2ULURU Discussions to Acquire York Pharma plc Are Currently Terminated 12776 1ULURU Discussions to Acquire York Pharma plc Are Currently Terminated 12776 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 1Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4645 6Migraine Frequency Tied to Stroke Heart Attack Risk 49976 1Migraine Frequency Tied to Stroke Heart Attack Risk 49976 2Migraine Frequency Tied to Stroke Heart Attack Risk 49976 3
...nternational GIANT (Genetic Investigation of Anthr...overy of obesity genes. So far, the scientists hav...-wide association studies with a total of more tha...date genes were validated in 14 further studies in...O and MC4R genes already known, it was now possibl...
...DELPHIA A study published in Cancer Prevention R...r Cancer Research, identifies components of black ...earchers at the Ohio State Comprehensive Cancer Ce...s in black raspberries, inhibited growth and stimu...ith an esophageal carcinogen. , "Our data provid...
...nzyme machine that translates a cell,s DNA code in...rial perfectionist. , Johns Hopkins researchers,...a new "proofreading step" during which the suite o...es errors, just after making them, and definitivel...tton. , It turns out, the Johns Hopkins researche...
Other Biology News:Obesity starts in the head? 6 newly discovered genes for obesity have a neural effect 2Lost in translation 2
...ker consists of ten double-stranded RNAs, 10, 20, ...rs. The dsRNA Marker is an ideal size marker for d...ty bp RNA band including in the dsRNA Marker is ad...ation. The dsRNA Marker is manufactured for non-de...
... size markers are a mixture of Strep•Tag®...e markers provide precise size references for prot...h Coomassie blue. Because each of the proteins con...can also be detected by the Strep•Tag II Mono...
Mouse Anti-Human ACP2 Monoclonal Antibody, Unconjugated, Clone M1-4A12 from Novus Biologicals
...er rocking platform, 220 V, is used for agitation ...on of liquid cultures, staining and destaining of ...cker features variable speed control (8-40 rpm) an... rocker features two 29 x 21 cm platforms covered ...
Biology Products: